NRG-GY020

Closed to Accrual

Return to Protocol Table

A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed, Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer

Principal Investigator

Floor Backes, MD

Status

Closed to Accrual

Date Opened To Accrual

February 07 2020

Date Closed to Accrual

August 29 2022

Disease Site

Gynecologic [GY]

Uterine Corpus

Phase

III

Developmental Therapeutics

Primary Objective

To compare the 3-year recurrence-free survival of women with high intermediate risk (HIR) Stage I/II mismatch repair deficient (dMMR) endometrioid endometrial cancer treated with radiation and MK-3475 (pembrolizumab) versus radiation alone.

Patient Population

Women with Stage I or II endometrioid endometrial cancer with documented MMR deficiency.

Target Accrual

168

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.